Is severe recurrent hepatitis C more common after adult living donor liver transplantation?

Hepatology

Volumn 40, Issue 3, 2004, Pages 524-526

  Russo, Mark W ^a   Shrestha, Roshan ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INTERFERON;

DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; GENOTYPE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LIVING DONOR; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; RECURRENT DISEASE; RISK FACTOR; ADULT; NOTE;

ADULT; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; RECURRENCE;

EID: 4544383637     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20418     Document Type: Editorial

References (21)

1. Shiffman ML, Fisher RA, Stravitz RT, Luketic VA, Sanyal AJ, Mills AS, et al. Histologic analysis of recurrent hepatitis C virus infection following living donor and cadaveric liver transplantation. Liver Transpl, in press.
2. Rodriguez-Luna H, Vargas H, De Petris G, Byrne T, Moss A, Mulligan D, et al. Hepatitis C virus recurrence in living donor liver transplantation vs. cadaveric liver transplantation (abstract 34). Am J Transpl 2003;(3 Suppl 5):160.
3. Ghobrial RM, Amersi F, Farmer DG, Chen P, Anselmo DM, Baquerizo A, et al. Rapid and severe early HCV recurrence following adult living donor liver transplantation (Abstract 104). Am J Transpl 2002;2:163A.
4. Trotter JF, Schiano T, Wach M, Kim-Schluger L, Bak T, Everson G, et al. Preliminary report: hepatitis C occurs earlier and is more severe in living donor liver transplant recipients [Abstract 720]. Am J Transpl 2001;1(Suppl 1):316A.
5. Gordon FD, Pomfret EA, Pomposelli JJ, Keaveny A, Simpson MA, Lewis D, et al. The severity of recurrent hepatitis C (HCV) in living donor adult liver transplant (LDALT) recipient is the same as cadaver (CAD) recipients (Abstract 885). Am J Transpl 2004;4(Suppl 8):400A.
6. Gaglio PJ, Malireddy S, Levitt BS, Lapointe-Rudow D, Lefkowitch J, Kinkhabwala M, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003;9:1028-35.
7. Pan SH, Nissen NN, Steven DC, Neda N, Tan TT, Poordad FF, et al. Comparisons of rejection and hepatitis C recurrence in live donor and deceased donor liver transplantation (Abstract 498). Am J Transpl 2004;4 (Suppl 8):295.
8. Fahmy A, O'Mahony CA, Kaul H, Morgan GR, John D, Diflo T, et al. Living donor liver transplantation (LDLT) is safe and effective for hepatitis C recipients. Am J Transpl 2004 (Abstract 724);4(Suppl 8):355A.
9. Vlierberghe HV, Troisi R, Ricciardi S, Colle I, Praet M, Conoscitore P, Hesse UJ, de Hemptinne B. Hepatitis "C" recurrence (HCV) does not worsens general outcome in adult living donot liver transplantation. Am J Transpl 2003 (Abstract 1435);3(Suppl 5):520A.
10. Russo MW, Galanko J, Beavers K, Fired MW, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004;10:340-346.
11. Bozorgzadeh A, Jain A, Ryan C, Ornt D, Zand M, Mantry P, Lansing K, Orloff M. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. Transplantation 2004;77:1066-1090.
12. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. HEPATOLOGY 2004;40:699-707.
13. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Cordoba J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-84.
14. Belli LS, Samonakis DN, Alberti AB, Papatheodiridis GV, Vangeli M, Patch DW, Airoldi A, et al. Liver transplantation for HCV cirrhosis: Results are not getting worse in recent years. Am J Transpl 2004 (Abstract 918);4(Suppl 8):409.
15. Russo MW, Galanko JA, Zacks SL, Beavers KL, Fried MW, Shrestha R. Impact of Donor Age and Year of Transplant on Graft Survival in Liver Transplant Recipients with Chronic Hepatitis C. Am J Transpl 2004;4:1133-1138.
16. Stravitz RT, Shiftman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, Ashworth A, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004;10:850-858.
17. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, Farmer DG, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004;10:859-867.
18. Everson GT, Trotter JF. Role of adult living donor liver transplantation in patients with hepatitis C. Liver Transpl 2003;9 supl 2:564-8.
19. Honda M, Kaneko S, Matsushita E, Kobayashi K, Abell GA, Lemon SM. Cell cycle regulation of HCV internal ribosomal entry site-directed translation. Gastroenterology 2000;118:152-162.
20. Taber DJ, Dupuis RE, Fann AL, Andreoni K, Gerber DA, Fair JH, Johnson MW, Shrestha R. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver Transpl 2002;8:219-223.
21. Russo MW, LaPointe-Rudow D, Kinkhabwala, M, Emond J, Brown Jr. RS. Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation. Am J Transpl 2004;4:427-31.